Top Markets
Coin of the day
Onward Medical N.V. Onward Medical N.V.

Onward Medical N.V.

ONWD
Classificação em ações #20475
Onward Medical N.V. is a medical technology company dedicated to developing... Onward Medical N.V. is a medical technology company dedicated to developing innovative therapies for spinal cord injuries, operating both within the Netherlands and internationally. Among its primary offerings is ARCEX, a non-invasive, external platform. This system incorporates a wearable stimulator and a wireless programmer, designed to restore or significantly enhance hand and arm motor function for individuals living with spinal cord injuries. Complementing this is ARCIM, an implantable platform. ARCIM features an implantable pulse generator and a lead positioned near the spinal cord, empowering individuals with chronic paralysis to regain the ability to stand and walk, often with minimal or no external assistance. The company is also currently advancing the Up-LIFT Trial, a clinical study evaluating the safety and efficacy of ARCEX Therapy in restoring strength and mobility in the upper extremities of those affected by spinal cord injury. Established in 2014, Onward Medical N.V. maintains its headquarters in Eindhoven, Netherlands.
Preço da ação
$2.75
Valor de mercado
$128.44M
Variação (1 dia)
-2.11%
Variação (1 ano)
-53.60%
País
NL
Negociar Onward Medical N.V. (ONWD)

Categoria

Receita da Onward Medical N.V. (ONWD)
Receita em Aug 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Onward Medical N.V., a receita atual da empresa (TTM) é 0. Em 2026, a empresa obteve uma receita de 0 igual a a receita do ano 2026, que foi de 0. A receita é o valor total gerado pela venda de bens ou serviços. Ao contrário do lucro, nenhuma despesa é subtraída.
Histórico de receita da Onward Medical N.V. de 2026 a 2026
Receita no final de cada ano
Ano Receita Alterar
Não há dados suficientes para as datas fornecidas.
Receita de empresas similares ou concorrentes
Empresa Receita Diferença de Receita País
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH